GSK plc
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report?
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
Sonoro Gold upsizes private placement to C$15M amid investor demand
GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
Here's Why GSK (GSK) is a Strong Value Stock
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
ASML Holding NV: A Significant Exit in Mark Hillman's Q1 2026 Portfolio Adjustments
HSBC, BP and GSK combine in dividend-driven knock to Footsie
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults